| Drug Name |
Agalsidase beta |
| Drug ID |
BADD_D00049 |
| Description |
Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa]. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.[A220343]
Agalsidase beta was granted FDA approval on 24 April 2003.[L16383] |
| Indications and Usage |
For treatment of Fabry's disease (alpha-galactosidase A deficiency) |
| Marketing Status |
Prescription |
| ATC Code |
A16AB04 |
| DrugBank ID |
DB00103
|
| KEGG ID |
D03228
|
| MeSH ID |
C459420
|
| PubChem ID |
52918379
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
58468-0041; 58468-0040 |
| Synonyms |
agalsidase beta | Fabrazyme |
